We report a 58-year-old Japanese woman who presented with nephrotic syndrome. Steroid therapy and cyclosporine A administration were initiated, but hematological remission and renal response were not achieved. Renal biopsy revealed amyloid deposits in the mesangial region and the small arteries. Proteomic analysis based on laser microdissection and mass spectrometry showed that the amyloid deposits were composed of the constant region of the lambda light chain. She received vincristine, adriamycin, and dexamethasone therapy followed by high-dose melphalan and autologous stem cell transplantation, resulting in hematological complete remission and renal response with negative urinary Bence-Jones protein and proteinuria. Renal biopsy was performed four times during follow-up, demonstrating that amyloid deposits decreased gradually, while glomeruli showing global sclerosis increased from 3 to 62%. This case suggests that glomerular amyloid deposits can be cleared via tissue remodeling, if stem cells producing amyloid precursors are completely replaced by unrelated cells after stem cell transplantation.
Introduction
Amyloid light chain (AL) amyloidosis is the most common type of amyloidosis. AL amyloidosis causes damage to several organs due to accumulation of misfolded fragments of monoclonal light chains [1] . The kidney is one of the organs most frequently affected by AL amyloidosis, usually resulting in proteinuria and renal dysfunction [2] . In patients with renal AL amyloidosis, extracellular amyloid deposits are observed by light microscopy and enlargement of the amyloid-positive area is associated with renal dysfunction [3, 4] .
Thanks to progress in the treatment for AL amyloidosis, the estimated overall survival rate has improved from 28 to 50% in the past decade and the renal response rate has increased to 55% [5, 6] . On the other hand, it remains controversial, whether treatment for renal AL amyloidosis can achieve improvement in kidney histology [7] [8] [9] .
Here, we report a 58-year-old Japanese woman with primary AL amyloidosis who was treated with two courses of vincristine, adriamycin, and dexamethasone (VAD) therapy followed by high-dose melphalan (HDM) and autologous stem cell transplantation (ASCT). In this patient, sequential renal biopsy revealed significant regression of amyloid deposits over a 9-year period. We also discuss the effect of chemotherapy on primary amyloidosis.
Case report
In 2004, a 45-year-old Japanese woman was admitted to another hospital with leg edema and proteinuria (11 g/day). Nephrotic syndrome was diagnosed and treatment was initiated with two courses of intravenous steroid pulse therapy (methylprednisolone at 1 g/day for 3 days) followed by oral prednisolone (PSL; 50 mg/day) and cyclosporine A (CyA; 100 mg/day). Proteinuria subsided to 2.44 g/day, after which PSL and CyA were tapered to 10 mg/day and 75 mg/day, respectively. In 2008 (at age 49), proteinuria increased to 4.89 g/day and she was admitted to our hospital for evaluation. On admission, her height was 156 cm, weight was 46.1 kg, and blood pressure was 128/74 mmHg. Laboratory tests showed that serum total protein was 5.3 g/dL, albumin was 2.7 g/dL, and creatinine was 0.9 g/dL ( Table 1 ). Immunofixation was negative for serum M-protein. Proteinuria was 4.89 g/day and lambda-type urinary Bence-Jones protein (BJP) was positive. Bone marrow aspiration was performed and the findings excluded multiple myeloma. The electrocardiogram did not show diffused low-voltage QRS complexes and there was no thickening of the ventricular or atrial walls on echocardiography.
First renal biopsy
The renal biopsy specimen contained 32 glomeruli, with 4 showing global sclerosis. Mesangial cell proliferation was not noted, but periodic acid-Schiff (PAS) staining revealed diffused and massive amorphous material in the mesangial and subendothelial regions. These deposits were negative for silver on periodic acid methenamine silver (PAM) staining. In addition, the deposits showed apple-green birefringence under polarizing light and were positive for Congo red staining and polarizing microscopy ( Fig. 1a -c) and for amyloid P, but were negative for amyloid A, beta-2 microglobulin, and transthyretin. Congo red staining was focally positive in the small arteries, interstitium, and tubules as well as in the glomerular lesions. It was unclear whether kappa or lambda chain deposition was predominant. Tubulointerstitial fibrosis occupied around 10% of the total renal cortical area. Immunofluorescence was negative for immunoglobulins (IgG, IgA, and IgM) and complement components (C3, C4, and C1q). Electron microscopy showed randomly arranged fibrils in the mesangial region that were 7-12 nm in diameter ( Fig. 1d ).
To investigate extra-renal involvement by amyloidosis, endoscopic biopsy of the colon was performed and amyloid deposits were confirmed ( Fig. 2 ). From these histological findings and the detection of lambda chain urinary BJP, a diagnosis of primary lambda-type systemic AL amyloidosis was made.
Clinical course
The patient received chemotherapy with two cycles of VAD and HDM followed by ASCT, according to the published criteria and regimen (7) . After 1 month, proteinuria showed a sudden decrease to 0.1 g/day and urinary BJP became negative. At the latest review in 2018, at age 58, complete hematologic response was maintained and proteinuria was < 0.15 g/day ( Fig. 3 ; Table 1 ).
Findings on sequential renal biopsy
In 2011, 2013, 2015, and 2017, the second to fifth renal biopsies were performed to determine whether further therapy was needed for the amyloid deposits in her kidneys. Light microscopy revealed that amorphous amyloid lesions identified by PAS, PAM, and Congo red staining showed considerable ongoing regression in the preserved glomeruli ( Fig. 1a-c) . Polarizing microscopy became negative after second renal biopsy. However, amyloid deposits were detected in sclerotic glomeruli and in the small arteries, including arterioles and interlobular arteries, and there was an increase of glomeruli with global sclerosis ( Table 2 ). Electron microscopy also demonstrated marked improvement of the renal amyloid deposits and randomly arranged fibrils were not detected in 2017 (Fig. 1d ). In 2017, biopsy of the colon was performed revealing that amyloid deposits had also diminished (Fig. 2 ).
Proteomic analysis with laser microdissection and mass spectrometry (LMD/MS)
Because the above-mentioned investigations of renal biopsy specimens failed to clarify light or heavy chain predominance, LMD/MA was performed with a paraffin section of the 2008 (year 7) biopsy specimen, according to the previously reported method [10] . The patient's amyloid was found to be consisted of the constant region of lambda light chain, leading to a final diagnosis of lambda-type AL amyloidosis.
Discussion
Treatment of AL amyloidosis has made considerable progress. Perz reported that 54% of the patients treated with VAD and HDM followed by ASCT, achieved overall hematological remission and that 31% of those with nephrotic syndrome showed clinical remission of nephrotic syndrome [8] . In addition, Jaccard stated that HDM followed by ASCT achieved CR in 61% of patients and organ response in 45% [9] . Furthermore, HDM plus ASCT led to CR in 43% of the patients according to Cibeira, with 78% of them achieving organ response [11] . Moreover, several clinical trials of new therapies for AL amyloidosis are ongoing [12] .
Removal of AL amyloid deposits from the mesangial region of the kidney is slow, because these deposits represent accumulations of fibrils composed of scarcely soluble monoclonal light chains. However, turnover of amyloid deposits occurs in vivo, so regression is possible if the supply of fibril precursors can be reduced [13] . It has been reported that amyloid deposits are removed from organs with rapid turnover of cellular components. For example, Katoh et al. demonstrated the clearance of AL amyloid deposits from the gastric mucosa after hematological complete remission was achieved [14] . On the other hand, it remains controversial whether amyloid deposits are removed from the mesangial region of the kidney after hematologic complete remission, because turnover of the glomerular matrix is slow [15] . Several authors have reported that amyloid deposits are not removed from the kidneys despite hematological remission and renal response. Yamazaki detected amyloid deposits in the kidneys at 8 months after complete disappearance of both proteinuria and M-protein. They suggested that whether clinical remission should correspond to histological remission may need consideration in the future [16] . Iwadate et al. found that amyloid deposits were not reduced at 11 years after their patient achieved hematological complete remission and renal response by treatment with VAD plus HDM and ASCT [17] . In contrast, Nakayama reported that renal amyloid deposits were decreased by treatment with melphalan and prednisolone plus dimethyl sulfoxide in a patient with primary AL amyloidosis, although there was an increase in glomeruli showing global sclerosis from 10 to 67% [18] . However, there have not been any reports about complete removal of amyloid deposits from preserved glomeruli.
The reason why renal amyloid deposits are not reduced in some cases and markedly reduced in others at the complete remission state is unknown. Moreover, the reason why in some cases clinical remission is obtained even though renal amyloid deposits are not reduced is unknown. Turnover time of the glomerular matrix or the quantity of amyloid deposits may be associated with the difference. Further research is required.
In conclusion, we reported a patient with AL amyloidosis in whom amyloid deposits showed marked reduction in the preserved glomeruli over time, although there was an increase of glomeruli with global sclerosis. This case suggests that glomerular amyloid deposits can be cleared by tissue remodeling, if stem cells producing amyloid precursors are completely replaced by unrelated stem cells after ASCT, thus removing the source of amyloid.
